🔴 Humacyte is trading 6% down with no clear new catalyst

Humacyte is trading at $0.41, down 5.81% on October 26, 2026, with no clear new company-specific catalyst identified.

• Positive V012 Phase 3 results announced October 23 met the trial’s primary endpoint, but do not explain the decline on October 26.
• Major indices are modestly higher, so the supplied market context does not establish a broad-market explanation.